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Chemokine receptors CCR3 and CCR4 are preferentially expressed by TH2 cells, mast
cells, and/or eosinophils, all of which are involved in the pathogenesis of allergic diseases.
Therefore, CCR3 and CCR4 have long been highlighted as potent therapeutic targets for
allergic diseases. Japanese traditional herbal medicine Kampo consists of multiple crude
drugs/herbs, which further consist of numerous chemical substances. Recent studies
have demonstrated that such chemical substances appear to promising sources in the
development of novel therapeutic agents. Based on these findings, we hypothesize that
Kampo-related crude drugs/herbs would contain chemical substances that inhibit the
cell migration mediated by CCR3 and/or CCR4. To test this hypothesis, we screened
80 crude drugs/herbs to identify candidate substances using chemotaxis assay. Among
those tested, Ephedra Herb inhibited the chemotaxis mediated by both CCR3 andCCR4,
Cornus Fruit inhibited that mediated by CCR3, and Rhubarb inhibited that mediated by
CCR4. Furthermore, Ephedra Herb specifically inhibited the chemotaxis mediated by not
only CCR3 and CCR4 but CCR8, all of which are selectively expressed by TH2 cells. This
result led us to speculate that ephedrine, a major component of Ephedra Herb, would
play a central role in the inhibitory effects on the chemotaxis mediated by CCR3, CCR4,
and CCR8. However, ephedrine exhibited little effects on the chemotaxis. Therefore, we
fractionated Ephedra Herb into four subfractions and examined the inhibitory effects of
each subfraction. As the results, ethyl acetate-insoluble fraction exhibited the inhibitory
effects on chemotaxis and calcium mobilization mediated by CCR3 and CCR4 most
significantly. In contrast, chloroform-soluble fraction exhibited a weak inhibitory effect on
the chemotaxis mediated by CCR8. Furthermore, maoto, one of the Kampo formulations
containing Ephedra Herb, exhibited the inhibitory effects on the chemotaxis mediated by
CCR3, CCR4, and CCR8. Taken together, our data suggest that these crude drugs/herbs
might be useful sources to develop new drugs targeting TH2-mediated allergic diseases.
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INTRODUCTION
Chemokines are a structurally related set of proteins which,
in coordination, recruit various leukocytes into target sites
via corresponding receptors. In human, there are at least
44 chemokines and 18 signal transducing receptors (Zlotnik
and Yoshie, 2000, 2012; Yoshie et al., 2001). Chemokines
play important roles in various biological processes such
as homeostatic migration and the homing of lymphocytes,
inflammatory mobilization of leukocytes, cell migration,
and homing during development, angiogenesis, and cancer
metastasis (Fujita et al., 2015). Chemokine receptors belong
to the seven-membrane G protein-coupled receptor (GPCR)
family (Zlotnik and Yoshie, 2000; Yoshie et al., 2001; Zlotnik
and Yoshie, 2012). As a number of drugs targeting GPCRs
have been successfully developed thus far (Wood and Armour,
2005; Subramaniam et al., 2012; Martin-Blondel et al., 2016),
chemokine-chemokine receptor axes are considered to be
promising drug targets for inflammatory and immunological
diseases.
Allergic inflammation is a critical feature of several allergic
diseases such as atopic dermatitis, allergic rhinitis, and asthma
(Ng and Wang, 2015; Pols et al., 2016; Weidinger and
Novak, 2016). In particular, TH2 cells, mast cells, and
eosinophils are involved in the pathogenesis of these allergic
diseases as major effector cells (Wynn, 2015). In this regard,
TH2 cell-derived cytokines such as IL-4, IL-5, and IL-13
stimulate IgE production by B cells, and induce migration,
activation, and growth of mast cells and eosinophils (Del
Prete, 1998). Thus, the selective migration of these effector
cells results in allergic inflammation. Therefore, a potent
strategy to overcome the allergic diseases would be to
interfere with the migration of such effector cells. In this
regard, CC chemokine receptor 3 (CCR3) is selectively
expressed by eosinophils, basophils, and a part of TH2 cells
that play major roles in allergic diseases (Daugherty et al.,
1996; Kitaura et al., 1996; Sallusto et al., 1997; Uguccioni
et al., 1997). The following CC chemokines function as
ligands for CCR3: eotaxin/CCL11, eotaxin-2/CCL24, eotaxin-
3/CCL26, RANTES/CCL5, MCP-2/CCL8, MCP-3/CCL7, and
MCP-4/CCL13 (Daugherty et al., 1996; Kitaura et al., 1996,
1999; Ponath et al., 1996; Forssmann et al., 1997; Heath
et al., 1997). Among them, the three eotaxins (CCL11, CCL24,
and CCL26) exhibit the highest specificity for CCR3 (Yoshie
et al., 2001; Zlotnik and Yoshie, 2012). In addition, their
expression levels frequently increase in allergic inflammatory
sites (Blanchard et al., 2006). The chemokine CCR4 is dominantly
expressed by TH2 cells (Yamamoto et al., 2000), and its
ligands are CCL17 and CCL22 (Imai et al., 1997, 1998). The
importance of the CCR4 axis in allergic diseases has been
demonstrated in mouse models of atopic dermatitis and asthma
(Gonzalo et al., 1999; Vestergaard et al., 1999; Kawasaki et al.,
2001). Furthermore, we and others have demonstrated that
the serum levels of CCL17 and CCL22 substantially increase
in patients with allergic diseases (Kakinuma et al., 2001,
2002; Fujisawa et al., 2002; Horikawa et al., 2002) and that
the serum levels of CCL17 correlate particularly with the
disease activities of atopic dermatitis (Kataoka, 2014). Based on
these data, the Japanese Pharmaceutical and Medical Devices
Agency has approved a serum CCL17 ELISA kit (Alaport R©
TARC) as a clinical examination tool for atopic dermatitis.
Collectively, these data strongly suggest that CCR3 and CCR4
are important therapeutic targets for a variety of allergic
diseases.
Japanese traditional herbal medicine Kampo, which has
a long-lasting history, consists of multiple crude drugs/herbs,
which further consist of numerous chemical substances (Hijikata,
2006). Over 140 Kampo formulations have been approved as
ethical drugs in Japanese Pharmacopeia and used clinically for
a variety of diseases. Some Kampo formulations are effective
in the treatment of inflammatory diseases (Shimizu, 2013).
In particular, maoto contains Ephedra Herb, and its major
component of Ephedra Herb is an alkaloid ephedrine (The
Ministry of Health, Labour and Welfare, 2011). Ephedrine is
known to bronchodilating activities and anti-inflammatory
effects (The Ministry of Health, Labour and Welfare, 2011).
Taken together, these observations suggest that the chemical
substances in Kampo-related crude drugs/herbs may be
promising sources in the development of novel therapeutic
agents.
Based on these findings, we hypothesize that Kampo-related
crude drugs/herbs would contain chemical substances that
inhibit the cell migration mediated by CCR3 and/or CCR4.
To test this hypothesis, we screened 80 crude drugs/herbs to
identify candidate substances. Among those tested, three extracts
(Cornus Fruit, Rhubarb, and Ephedra Herb) inhibited the cell
migration mediated by CCR3 and CCR4. Furthermore, Ephedra
Herb specifically inhibited the cell migration mediated by not
only CCR3 and CCR4 but CCR8, all of which are selectively
expressed by TH2 cells. Consistently, maoto, one of the Kampo
formulations containing Ephedra Herb, showed potency to
inhibit the cell migration mediated by CCR3, CCR4, and CCR8.
Taken together, our data suggest that these crude drugs/herbs
might be useful sources to develop new drugs targeting TH2-
mediated allergic diseases.
MATERIALS AND METHODS
Crude Drugs/Herbs and Reagents
Crude drugs/herbs were dissolved in H2O at a concentration
of 10 mg/ml, and the stock solutions were stored at −80◦C.
The voucher samples of these extracts were reserved in the
Cooperative Research Project of Institute of Natural Medicine
at University of Toyama. Ephedrine was purchased from Nichi-
Iko (Toyama, Japan) Recombinant human chemokines were
purchased from R&D Systems (Minneapolis, MN).
Cells
A mouse pre-B cell line L1.2 was kindly given by Dr. E. Butcher
(Stanford University School of Medicine, Stanford, CA). The
panels of L1.2 cell lines that stably express human chemokine
receptors were generated using a retroviral vector pMX-IRES-
EGFP as described previously (Yoshida et al., 1999).
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Chemotaxis Assay
The procedure has been described previously (Nakayama et al.,
2004). Briefly, chemotaxis assays were performed using 96-well
chemoTx chamber (Neuroprobe, Gaithersburg, MD). Cells that
migrated into the lower wells were lysed with 0.1% Triton X-100
(Wako, Osaka, Japan) and quantified using PicoGreen dsDNA
reagent (Thermo Fisher Scientific, Waltham, MA).
Calcium Mobilization Assay
The procedure has been described previously (Nakayama et al.,
2010). Briefly, cells were loaded with 3 µM fura 2-AM
fluorescence dye (Thermo Fisher Scientific). After washing, the
cells were placed on a F3000 fluorescence spectrophotometer
(Hitachi, Tokyo, Japan) and stimulated with each recombinant
human chemokine. Emission fluorescence at 510 nm was
measured upon excitation at 340 and 380 nm, and the
fluorescence intensity ratio (R340/380) was obtained.
Extraction
Dried stems and leaves of Ephedra sinica stapf (50 g) were boiled
in 500 mL H2O for 50 min, and the decoction was filtered. The
filtrate was concentrated through depressurization, and the H2O
extract (5.22 g) was further suspended in ethyl acetate (EtOAc).
The EtOAc phase was extracted and evaporated in vacuo to yield
the following fractions: 0.8 g of AcOEt-insoluble fraction, 0.2 g
of AcOEt-eluted fraction, and H2O-eluted fraction. The H2O-
eluted fraction was titrated with HCl and further partitioned
between CH3Cl and 25% ammonia solution to yield extracts of
2.8 and 1.1 g, respectively.
Statistical Analyses
The procedure has been described previously (Otsubo et al.,
2015; Yasuda et al., 2015). Briefly, Student’s t-test was performed
to analyze differences between two groups; one-way analysis of
variance (ANOVA) with Holm’s post-hoc test was performed for
multiple groups. All data were analyzed using R Environment
(R Development Core Team, Vienna, Austria) with EZR plugin
version (Kanda, 2013). P < 0.05 was considered to be statistically
significant.
RESULTS
Ephedra Herb Inhibits the Chemotaxis
Mediated by CCR3, CCR4, and CCR8
To identify candidates of CCR3 and CCR4 antagonists from
a crude drug/herb library, we screened 80 crude drugs/herbs
(Table 1) based on chemotaxis assays using L1.2 cell lines that
stably express CCR3 (L1.2-CCR3; Figure 1A) and CCR4 (L1.2-
CCR4; Figure 1B). As the results, Ephedra Herb inhibited the
cell migration of both L1.2-CCR3 and L1.2-CCR4, Cornus Fruit
inhibited that of L1.2-CCR3, and Rhubarb inhibited that of
L1.2-CCR4 (Figures 1A,B). We confirmed that there were no
cytotoxicity at these concentrations using a cell viability assay
(data not shown). Among the crude drugs/herbs tested, we
decided to focus on Ephedra Herb because it most effectively
inhibited the cell migration mediated by both CCR3 and CCR4.
Given that CCR3 and CCR4 have structural similarity to CCR1,
CCR2, CCR5, and CCR8, we next examined the receptor
specificity of Ephedra Herb using L1.2-CCR1, L1.2-CCR2, L1.2-
CCR3, L1.2-CCR4, L1.2-CCR5, and L1.2-CCR8 (Figure 1C). As
the results, Ephedra Herb specifically inhibited the chemotaxis
mediated by CCR8 in addition to CCR3 and CCR4. As TH2
cells selectively express CCR3, CCR4, and CCR8, these data
suggest that Ephedra Herb has a potency to strongly suppress cell
migration of TH2 cells and TH2 cell-mediated allergic reactions.
Ethyl Acetate (EtOAc)-Insoluble Fraction of
Ephedra Herb Inhibits the Chemotaxis
Mediated by CCR3 and CCR4
Next, we sought to identify constituents that inhibit the
chemotaxis mediated by CCR3 and CCR4. As described above,
ephedrine is a major component of Ephedra Herb and possesses
bronchodilating activities and anti-inflammatory effects. We
therefore addressed whether ephedrine could inhibit the cell
migration mediated by CCR3, CCR4, and/or CCR8. However,
ephedrine exhibited little inhibitory effects on the cell migration
of L1.2-CCR3, L1.2-CCR4, and L1.2-CCR8 (Figure 2A). This
result led us to seek for other constituents except ephedrine
that inhibit the chemotaxis mediated by CCR3, CCR4, and
CCR8. To this end, we fractionated Ephedra Herb to the
following four subfractions: EtOAc-soluble (fraction 1), EtOAc-
insoluble (fraction 2), CH3Cl-soluble (fraction 3), and water-
eluted (fraction 4) (Figure 2B). The EtOAc-insoluble fraction
(fraction 2) exhibited significant inhibitory effects on the
chemotaxis of L1.2-CCR3 and L1.2-CCR4 but not on that of
L1.2-CCR8. In contrast, the CH3Cl-soluble fraction (fraction 3)
partially inhibited the chemotaxis of L1.2-CCR8 alone.
As the EtOAc-insoluble fraction exhibited the significant
inhibitory effects on CCR3 and CCR4, we then sought to
quantify the inhibitory effects of Ephedra Herb and the EtOAc-
insoluble fraction. As the results, both Ephedra Herb and the
EtOAc-insoluble fraction inhibited the chemotaxis mediated by
CCR3 and CCR4 in a dose-dependent manner (Figure 2C).
Furthermore, the inhibitory effects of the EtOAc-insoluble
fraction (CCR3: EC50 = 31.1 µg/ml; CCR4: 72.1 µg/ml)
was significantly stronger than that of Ephedra Herb (CCR3:
EC50 = 81.3 µg/ml; CCR4: 295.5 µg/ml). We next sought to
confirm the receptor specificity of the EtOAc-insoluble fraction
of Ephedra Herb (Figure 2D). As the results, the EtOAc-
insoluble fraction significantly inhibited the chemotaxis of L1.2-
CCR3 and L1.2-CCR4 whereas this fraction partially inhibited
the chemotaxis of L1.2-CCR1. In addition, the EtOAc-insoluble
fraction significantly inhibited the calcium mobilization induced
by CCR3 and CCR4 (Figure 2E). Taken together, these data
suggest that the EtOAc-insoluble fraction of Ephedra Herb
contains the constituents that function as an antagonist against
CCR3 and CCR4 at high levels.
EtOAc-Insoluble Fraction of Ephedra Herb
Inhibits all Ligand-Induced Chemotaxis
Mediated by CCR3 and CCR4
Subsequently, we addressed whether the EtOAc-insoluble
fraction would antagonize any specific ligands for CCR3 and
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TABLE 1 | The list of a crude drug/herb library.
No. Crude drugs/herbs No. Crude drugs/herbs No. Crude drugs/herbs
1 Artemisia Capillaris Flower 31 Saffron 61 Japanese Angelica Root
2 Turmeric 32 Gardenia Fruit 62 Peach Kernel
3 Corydalis Tuber 33 Cornus Fruit 63 Ginseng
4 Astragalus Root 34 Zanthoxyrum Fruit 64 Fritillaria Bulb
5 Scutellaria Root 35 Jujube Seed 65 Ophiopogon Tuber
6 Phellodendron Bark 36 Rehmannia Root 66 Mentha Herb
7 Coptis Rhizome 37 Eleutherococcus senticosus 67 Pinellia Tuber
8 Polygala Root 38 Lycium Bark 68 Angelica Dahurica Root
9 Zedoary 39 Processed Rehmannia Root 69 Atractylodes Rhizome
10 Pueraria Root 40 Peony Root 70 Areca
11 Trichosanthes Root 41 Plantago Seed 71 Poria Sclerotium
12 Processed Ginger 42 Ginger 72 Processed Aconite Root
13 Glycyrrhiza 43 Cimicifuga Rhizome 73 Sinomenium Stem and Rhizome
14 Platycodon Root 44 Magnolia Flower 74 Saposhnikovia Root and Rhizome
15 Chrysanthemum Flower 45 Red Peony Root 75 Moutan Bark
16 Immature Orange 46 Cnidium Rhizome 76 Ephedra Herb
17 Notopterygium 47 Atractylodes Lancea Rhizome 77 Hemp Fruit
18 Apricot Kernel 48 Mulberry Bark 78 Coix Seed
19 Sophora Root 49 Perilla Herb 79 Japanese Gentian
20 Schizonepeta Spike 50 Rhubarb 80 Forsythia Fruit
21 Cinnamon Bark 51 Jujube
22 Red Ginseng 52 Alisma Rhizome
23 Cyprus Rhizome 53 Panax Japonicus Rhizome
24 Magnolia Bark 54 Anemarrhena Rhizome
25 Achyranthes Root 55 Clove
26 Euodia Fruit 56 Uncaria Hook
27 Burdock Fruit 57 Polyporus Sclerotium
28 Schisandra Fruit 58 Citrus Unshiu Peel
29 Bupleurum Root 59 Gastrodia Tuber
30 Asiasarum Root 60 Asparagus Tuber
CCR4 (Figure 3). To this end, we used CCL11, CCL24,
CCL26, CCL13, and CCL5 as CCR3 ligands and CCL17 and
CCL22 as CCR4 ligands. As the results, the EtOAc-insoluble
fraction inhibited all ligand-induced chemotaxis of L1.2-CCR3
(Figure 3A) and L1.2-CCR4 (Figure 3B). These data suggest that
the EtOAc-insoluble fraction possesses no specific antagonizing
activities against the ligands for CCR3 and CCR4 but does
directly inhibit these receptors.
Maoto Inhibits the Chemotaxis Mediated
by CCR3, CCR4, and CCR8
Maoto is one of the Kampo formulations containing Ephedra
Herb and most commonly used in clinical settings. Therefore,
we gave importance to examine the inhibitory effects of maoto
on the chemotaxis via CCR3, CCR4, as well as CCR8 (Figure 4).
As the results, maoto inhibited the chemotaxis of L1.2-CCR3
(Figure 4A), L1.2-CCR4 (Figure 4B), and partially L1.2-CCR8
(Figure 4C) in a dose dependent manner, which is consistent
with our observation in Ephedra Herb (Figure 1C). These results
suggested that maoto has a potency to inhibit TH2 cell migration.
DISCUSSION
Allergic diseases are caused by a TH2-dominant condition, which
is characterized by the infiltration of Th2 cells, eosinophils,
and mast cells. TH1 and TH2 cells express distinct patterns
of chemokine receptors that enable selective migration toward
different types of inflammation. TH2 cells preferentially express
CCR3, CCR4, and CCR8 while Th1 cells preferentially express
CCR5 and CXCR3. Furthermore, CCR3 is the major receptor
expressed on eosinophils and basophils. Thus, CCR3 and CCR4
have been paid attention as potent therapeutic targets for
allergic diseases. In this study, we demonstrated that three crude
drugs/herbs to possess the antagonist activities against CCR3 and
CCR4 (Figure 1A). Among them, Ephedra Herb exhibited the
potency to inhibit the cell migration mediated by not only CCR3
and CCR4 but also CCR8 (Figure 1C).
Ephedra Herb, which is listed in the Japanese Pharmacopeia
(JPXVI) (The Ministry of Health, Labour and Welfare, 2011)
has been used in traditional Chinese formulations and Kampo,
formulations for inducing perspiration, healing a cold, relieving
cough, and dilating the bronchial tubes. We showed that maoto,
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 June 2016 | Volume 4 | Article 54
Matsuo et al. Ephedra Herb Inhibits TH2 Chemotaxis
FIGURE 1 | Ephedra Herb inhibits the chemotaxis mediated by CCR3, CCR4, and CCR8. (A), Cell migration assay was performed using L1.2 cells stably
expressing CCR3 (L1.2-CCR3) and 10 nM CCL11 in the presence of each crude drug/herb extract at 10 µg/ml (open columns) or 100 µg/ml (closed columns). Each
experiment was repeated three times. Cell migration activity is shown in a percentage relative to the control (mean ± SE). (B), Cell migration assay was performed
using L1.2-CCR4 and 10 nM CCL22 in the presence of each extract at 10 µg/ml (open columns) or 100 µg/ml (closed columns). (C), Cell migration assay was
performed using the following cells and corresponding chemokines in the presence of Ephedra Herb at 10 µg/ml (open columns) or 100 µg/ml (closed columns):
L1.2-CCR1/CCL5, L1.2-CCR2/CCL2, L1.2-CCR3/CCL11, L1.2-CCR4/CCL22, L1.2-CCR5/CCL5, and L1.2-CCR8/CCL1. Each chemokine was used at 10 nM.
P-values were based on ANOVA with Holm’s post-hoc test (A,B) and Student’s t-test (C). *P < 0.05 and **P < 0.01 compared with the controls.
a Kampo formulation containing Ephedra Herb, inhibits the cell
migration mediated by CCR3, CCR4, and CCR8 (Figure 4). In
addition to Ephedra Herb, maoto consists the following three
more medical herbs: Glycyrrhiza, Apricot Kernel, and Cinnamon
Bark. However, the extracts of Glycyrrhiza, Apricot Kernel,
and Cinnamon Bark exhibited no inhibitory effects on CCR3
and CCR4 (Table 1 and Figure 1A). Therefore, we concluded
that Ephedra Herb plays a central role in the inhibition of
CCR3 and CCR4 (Figures 2, 3). In turn, Ephedra Herb and
Ephedra Herb-containing Kampo formulations such as maoto
would effectively suppress TH2-mediated allergic inflammation.
Historically, maoto has been widely used for the treatment of
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FIGURE 2 | Ethyl acetate (EtOAc)-insoluble fraction of Ephedra Herb inhibits the chemotaxis mediated by CCR3 and CCR4. (A), Cell migration assay was
performed using the following cells and corresponding chemokines in the presence of ephedrine at the indicated concentrations: L1.2-CCR3/CCL11,
L1.2-CCR4/CCL22, and L1.2-CCR8/CCL1. Unfractionated Ephedra Herb was used as a control. Each chemokine was used at 10 nM. Each experiment was
repeated three times. Cell migration activity is shown in a percentage relative to the control (mean ± SE). (B), Cell migration assay was performed using
L1.2-CCR3/CCL11, L1.2-CCR4/CCL22, and L1.2-CCR8/CCL1 in the presence of each fraction of Ephedra Herb at 100 µg/ml. (C), Cell migration assay was
performed as described in the panel (B) in the presence of Ephedra Herb and its EtOAC-insoluble fraction at the indicated concentrations. EC50 was also calculated.
(D), Cell migration assay was performed using the following cells and corresponding chemokines in the presence of EtOAC-insoluble fraction of Ephedra Herb at 0
µg/ml (open column), 10 µg/ml (closed columns), or 100 µg/ml (gray columns): L1.2-CCR1/CCL5, L1.2-CCR2/CCL2, L1.2-CCR3/CCL11, L1.2-CCR4/CCL22,
L1.2-CCR5/CCL5, and L1.2-CCR8/CCL1. Each chemokine was used at 10 nM. (E), Calcium mobilization assay was performed using L1.2-CCR3/CCL11 and
L1.2-CCR4/CCL22 in the presence of Ephedra Herb and its EtOAC-insoluble fraction. The cells were loaded with fura 2-AM and stimulated with the corresponding
chemokines at 10 nM with or without Ephedra Herb and its EtOAC-insoluble fraction at 100 µg/ml. Intracellular calcium mobilization was measured on a fluorescence
spectrophotometer. Each experiment was repeated three times; representative results are presented. P-values were based on ANOVA with Holm’s post-hoc test (B)
and Student’s t-test (A,D). *P < 0.05 and **P < 0.01 compared with the controls.
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FIGURE 3 | EtOAc-insoluble fraction of Ephedra Herb inhibits all
ligand-induced chemotaxis mediated by CCR3 and CCR4. (A), Cell
migration assay was performed using L1.2-CCR3 and the following
chemokines in the presence of the EtOAC-insoluble fraction of Ephedra Herb
at 0 µg/ml (open column), 10 µg/ml (closed column), or 100 µg/ml (gray
column): CCL11, CCL24, CCL26, CCL13, and CCL5. Each chemokine was
used at 10 nM. (B), Cell migration assay was performed using L1.2-CCR4,
CCL22, and CCL17 in the presence of the EtOAC-insoluble fraction of
Ephedra Herb at 0 µg/ml (open columns), 10 µg/ml (closed columns), or 100
µg/ml (gray columns). Both chemokines were used at 10 nM. Each
experiment was repeated three times; representative results are presented.
Cell migration activity is shown in a percentage relative to the control (mean ±
SE). P-values were based on Student’s t-test. *P < 0.05 and **P < 0.01
compared with the controls.
febrile symptoms caused by viral infection. In addition it has
recently been shown to suppress ovalbumin-induced asthma and
inhibit the recruitment of eosinophils into lung tissues in mice
(Ma et al., 2014). Furthermore, it has been shown to decrease
IL-4 levels and increase IFN-γ levels in the bronchoalveolar
lavage fluid (Ma et al., 2014). In this regard, TH2 cell-derived
cytokines such as IL-4, IL-5, and IL-13 play a critical role in the
pathogenesis of allergic reaction (Brandt and Sivaprasad, 2011);
IL-4 and IL-13 stimulate IgE production, and IL-5 is responsible
for eosinophil growth, differentiation, migration, activation, and
survival (Del Prete, 1998). Based on these findings, Ephedra
Herb-containing Kampo formulations such as maoto appear to
possess potent activities to strongly affect the TH1/TH2 balance.
Maoto is prescribed to patients with influenza in Japan. A
recent clinical study has demonstrated that maoto has equivalent
clinical efficacy to that of neuraminidase inhibitors such as
FIGURE 4 | Maoto inhibits the chemotaxis mediated by CCR3, CCR4,
and CCR8. Cell migration assay was performed using the following cells and
corresponding chemokines in the presence of maoto at the indicated
concentrations: L1.2-CCR3/CCL11 (A), L1.2-CCR4/CCL22 (B), and
L1.2-CCR8/CCL1 (C). Each chemokine was used at 10 nM. Each experiment
was repeated three times; representative results are presented. Cell migration
activity is shown in a percentage relative to the control (mean ± SE). P-values
were based on Student’s t-test. *P < 0.05 and **P < 0.01 compared with the
controls.
oseltamivir and zanamivir (Nabeshima et al., 2012). Ephedra
Herb inhibits the growth of influenza virus A/PR/8/34 (H1N1)
by suppressing acidification of cellular components such as
endosomes and lysosomes that are essential for the uncoating
process of influenza virus in host cells (Mantani et al., 1999).
These observations suggest that maoto may also have direct
anti-influenza virus activities. TH1 cells mainly produce IFN-
γ, IL-2, and IL-12 and play a critical role in cell-mediated
immune responses and therefore the clearance of viral infection
(Lucin et al., 1992; Schijns et al., 1995); TH1 polarization is
essential for the protective activity against influenza (Gu et al.,
2011). In this study, we demonstrated that maoto selectively
inhibits chemotaxis mediated by the TH2-relevant chemokine
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receptors (Figure 4). Taken together, one of the underlying
mechanisms by which maoto exhibits the anti-influenza activities
might be to suppress TH2 cell-mediated immune responses
by inhibiting cell migration of TH2 cells toward inflammation
sites.
As described above, Ephedra Herb contains an alkaloid
component ephedrine, which has bronchodilating activities
as wells as anti-inflammatory effects. Nevertheless, ephedrine
exhibited no inhibitory effect on the chemotaxis mediated
by CCR3, CCR4, and CCR8 in this study. In contrast, we
demonstrated that the EtOAc-insoluble fraction (fraction 2) and
the CH3Cl-soluble fraction (fraction 3) of Ehpedra Herb include
antagonistic components against CCR3, CCR4, and CCR8
(Figures 4A,B). Further investigation of compounds responsible
for the antagonist activities in these fractions may lead to develop
novel therapeutic agents for allergic diseases.
Among the tested crude drugs/herbs except for Ephedra Herb,
Cornus Fruit inhibited the CCR3-mediated chemotaxis, and
Rhubarb inhibited the CCR4-mediated chemotaxis, respectively.
Cornus Fruit, which is listed in JPXVI, has been used for
improving liver and kidney functions in Kampo medicine.
Rhubarb, which is also listed in JPXVI, has been used as laxative
and anti-inflammatory agents. These crude drugs/herbs also
may have potent anti-allergic activities. Further examinations
are indispensable to clarify the detail mechanisms of these
components and identify responsible constituents.
In the current study, we successfully identified three crude
drugs/herbs with the antagonist activity against CCR3 and CCR4
by chemotaxis assays from 80 crude drugs/herbs. In particular,
we demonstrated that Ephedra Herb is a potential medical
agent for TH2-mediated allergic diseases by inhibiting the cell
migration mediated by the TH2-relevant chemokine receptors
such as CCR3, CCR4, and CCR8. This approach using a large
crude drug/herb library relevant to Kampo formulations and
chemotaxis assays appears to increase the opportunity to identify
compounds with immune regulations.
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